科技制造持续走热 芯擎科技完成超10亿元新融资｜投融资周报

Group 1 - The core focus of investment remains on artificial intelligence and the chip sector, with significant activity in the healthcare field as well [1][3] - Hubei Chipking Technology Co., Ltd. completed a B round financing exceeding 1 billion RMB, while Dream Sky Technology (Suzhou) Co., Ltd. announced over 100 million RMB in Pre-A++ and strategic round financing [1][30][51] - In the healthcare sector, Yingshi Biotechnology (Nanjing) Co., Ltd. secured over 34 million USD in C round financing led by Rehabilitation Capital [1][18] Group 2 - The technology and manufacturing sectors saw the highest number of financing events, with the chip sector completing 4 financing rounds totaling 1.24 billion RMB, and the AI sector completing 3 rounds exceeding 59 million RMB [3][4] - The financing activities were primarily concentrated in Jiangsu Province, Beijing, and Shanghai, with 12, 6, and 5 financing events respectively [5][6] Group 3 - Qiming Venture Partners and Yunze Capital were notably active, each completing 2 financing rounds mainly in the healthcare and technology sectors [7][8] - Notable financing events include: - Beijing Huimei Cloud Technology Co., Ltd. raised nearly 200 million RMB [9] - Jiaxing Zhitong Technology Co., Ltd. completed several million RMB in A+ round financing [10] - Kegong Biotechnology (Hangzhou) Co., Ltd. raised several million RMB in A round financing [11] Group 4 - Other significant financing events include: - Microfar Biotechnology (Hangzhou) Co., Ltd. completed nearly 100 million RMB in Pre-A round financing [12] - Yixi Biotechnology (Suzhou) Co., Ltd. raised nearly 200 million RMB in A round financing [13] - Weicheng Medicine (Suzhou) Co., Ltd. secured several million USD in seed round financing [15] Group 5 - The financing landscape indicates a strong trend towards AI-driven solutions and advanced manufacturing technologies, with companies like Shenzhen Green Cloud Technology Co., Ltd. and Shanghai Kaibo Cloud Information Technology Co., Ltd. also securing significant funding [21][23] - The overall financing scale in the domestic primary market during the reported period reached approximately 4.486 billion RMB across 34 events [1][2]